title: Insulin-specific vaccination for type 1 diabetes: a step closer?
abstract: Vaccination against self-antigens to avert pathological immunity to self--'negative vaccination'--is the Holy Grail of autoimmune disease therapy. This approach depends on deletion or inactivation of pathogenic T cells, or induction of protective, 'regulatory' T cells. While effective in inbred rodent models, it is yet to be translated to humans. Reasons for this include its application only in end-stage disease, ignorance about antigen form, route of delivery and dose-schedule required for a bio-response, lack of meaningful and measurable bio-response markers, co-activation of pathogenic immunity and genetic heterogeneity.
authors.affiliation: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. harrison@wehi.edu.au
authors.forename: Leonard C
authors.initials: LC
authors.lastname: Harrison
mesh_terms: D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007328:Insulin / Q000276:immunology*; D014611:Vaccination / Q000379:methods*
chemical_list: D007328:Insulin